

LA JOLLA PHARMACEUTICAL CO

Form 8-K

March 10, 2004

**Table of Contents**

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549**

---

**FORM 8-K**

**CURRENT REPORT  
PURSUANT TO SECTION 13 or 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934**

Date of report (Date of earliest event reported): March 9, 2004

**La Jolla Pharmaceutical Company**

(Exact Name of Registrant as Specified in Charter)

Delaware (State or Other Jurisdiction of Incorporation)	0-24274 (Commission File Number)	33-0361285 (IRS Employer Identification No.)
------------------------------------------------------------------	----------------------------------------	----------------------------------------------------

6455 Nancy Ridge Drive, San Diego, California (Address of Principal Executive Offices)	92121 (Zip Code)
-------------------------------------------------------------------------------------------------	---------------------

Registrant's telephone number, including area code: (858) 452-6600

N/A

(Former Name or Former Address, if Changed Since Last Report)

---

---

**TABLE OF CONTENTS**

Item 5. Other Events and Required FD Disclosure

Item 7. Financial Statements, Pro Forma Financial Information and Exhibits

SIGNATURES

EXHIBIT INDEX

EXHIBIT 99.1

EXHIBIT 99.2

---

**Table of Contents**

**Item 5. Other Events and Required FD Disclosure.**

On March 9, 2004, the Company issued a press release announcing that Steven Engle, the Company's Chief Executive Officer, would present at the SG Cowen 24th Annual Healthcare Conference on March 11, 2004. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

On March 10, 2004, the Company issued a press release announcing that Gail Sloan was promoted to Vice President of Finance, Controller and Secretary. A copy of the press release is attached hereto as Exhibit 99.2 and is incorporated herein by reference.

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) *Exhibits.* The following exhibits are filed with this report on Form 8-K:

<b><u>Exhibit Number</u></b>	<b><u>Description of Exhibit</u></b>
99.1	Press Release announcing that the Company would present at the SG Cowen 24th Annual Healthcare Conference
99.2	Press Release announcing that Gail Sloan was promoted to Vice President of Finance, Controller and Secretary

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**LA JOLLA PHARMACEUTICAL  
COMPANY**

Date: March 10, 2004

By: /s/ Gail A. Sloan  
Gail A. Sloan  
Vice President of Finance and  
Controller

---

**Table of Contents**

**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description of Exhibit</b>
99.1	Press Release announcing that the Company would present at the SG Cowen 24th Annual Healthcare Conference
99.2	Press Release announcing that Gail Sloan was promoted to Vice President of Finance, Controller and Secretary